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Abstract
Background: The aim was to collate all myasthenia gravis (MG) epidemiological studies including AChR MG and MuSK 
MG specific studies. To synthesize data on incidence rate (IR), prevalence rate (PR) and mortality rate (MR) of the 
condition and investigate the influence of environmental and technical factors on any trends or variation observed.
Methods: Studies were identified using multiple sources and meta-analysis performed to calculate pooled estimates 
for IR, PR and MR.
Results: 55 studies performed between 1950 and 2007 were included, representing 1.7 billion population-years. For All 
MG estimated pooled IR (eIR): 5.3 per million person-years (C.I.:4.4, 6.1), range: 1.7 to 21.3; estimated pooled PR: 77.7 per 
million persons (C.I.:64.0, 94.3), range 15 to 179; MR range 0.1 to 0.9 per millions person-years. AChR MG eIR: 7.3 (C.I.:5.5, 
7.8), range: 4.3 to 18.0; MuSK MG IR range: 0.1 to 0.32. However marked variation persisted between populations 
studied with similar methodology and in similar areas.
Conclusions: We report marked variation in observed frequencies of MG. We show evidence of increasing frequency 
of MG with year of study and improved study quality. This probably reflects improved case ascertainment. But other 
factors must also influence disease onset resulting in the observed variation in IR across geographically and genetically 
similar populations.
Background
M y a s t h e n i a  g r a v i s  ( M G )  i s  a n  a r c h e t y p a l  a u t o i m m u n e
disorder in which muscle weakness occurs as a result of
impairment of neuromuscular transmission. It is likely to
occur as the result of a number of disease entities that
result in an indistinguishable clinical picture [1]. There
are paraneoplastic forms (thymoma-associated) and non-
paraneoplastic forms and the disorder is immunologically
heterogeneous - for example serum antibodies can be
detected to muscle acetylcholine receptors (AChR-Ab)
[2] or the muscle-specific receptor tyrosine kinase
(MuSK-Ab) [3], but not both in the same patient. From
case series and epidemiological studies, a bimodal distri-
bution of MG IR has been frequently described suggest-
ing a hormonal or environmental influence on disease
onset. MG occurs in both sexes, at all ages and in all races
[4].
A large number of MG epidemiological studies have
been performed worldwide over the last 60 years with
marked variability in observed incidence and prevalence
of the disease. Systematic review of MG epidemiology has
been carried out in the past by Phillips [5]; but 28 further
studies have been performed since and this review pre-
dates the discovery of MuSK-Ab MG. In his review, Phil-
lips commented upon apparent increasing IR and PR with
time but without similar change in MR, and proposed
that these trends were due to improved diagnosis and a
changing natural history of disease related to better treat-
ment.
The aim of this review was to summarize the findings
of all population-based epidemiological studies of myas-
thenia gravis (MG) paying attention to serological sub-
type-specific studies and age- and sex- specific incidence.
We sought to establish if there is a consensus in IR, PR
and MR of MG worldwide and investigate any trends or
differences in observed rates over time and in popula-
tions.
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Methods
To identify all relevant studies, 4 medical databases
(Pubmed, Medline, EMBASE, Cochrane library) and 2
proceedings databases (Zetoc, ISI proceedings) were
searched using 21 search terms as keywords or MESH
terms (Additional file 1 shows search strategy and terms
used). English and non-English studies were included and
non-English studies were translated when required. The
bibliographies of all included studies were searched and
the final list was discussed with experts in the field (Pro-
fessor Angela Vincent, Neurosciences group, Oxford; Dr J
McConville, Belfast). Good overlap between sources
assured almost complete ascertainment of relevant stud-
ies (See additional file 1).
All population-based epidemiological studies of myas-
thenia gravis were included and case series without a
defined denominator population were excluded. Inclu-
sion criteria for MG cases in individual studies were
broadly based on Osserman clinical criteria [6] with sup-
portive evidence from anti-acetylchoinesterase respon-
siveness, neurophysiological and serological testing.
There are no universally accepted and validated criteria
for the diagnosis of MG therefore we accepted all cases as
defined by the authors. The majority of studies consid-
ered all patients with a clinical diagnosis of MG together
(henceforth referred to as All MG). A proportion of stud-
ies performed in the past 20 years examined serological
MG subgroups separately: anti-acetylcholine receptor
antibody positive MG (AChR-MG) and anti-muscle spe-
cific kinase antibody positive MG (MuSK-MG). There
were no epidemiological studies on seronegative MG
(SNMG).
Crude data (number of incident cases, number of prev-
alent cases, prevalent population, number of population
years studied, and number of sources used for case ascer-
tainment, inclusion and exclusion criteria, final-year of
study and country of study) were extracted using a
piloted questionnaire. IR, PR and MR and exact 95% con-
fidence intervals (CI) based upon the Poisson distribution
were calculated using STATA (Copyright 1996-2009 Stata
Corp LP). Where the relevant crude data were available
(9 studies), a standardised IR was calculated to WHO
standard world population [7]. There was no significant
difference between crude and standardised rates so crude
rates are used throughout this review. Each included
study was graded as 'High', 'Intermediate' and 'Low' qual-
ity according to number of ascertainment sources used
and number of person years studied (details in additional
file 1). Search strategy, study selection, data extraction
and quality grading were performed by AC and indepen-
dently conducted by JMcC with good agreement.
Meta-analysis was performed using the random effects
model with 95% confidence intervals to the Poisson dis-
tribution. Heterogeneity was tested using Chi-squared
test and measured using the I2 statistic [8]. A value of I2 <
25% was chosen to represent an appropriate level of
homogeneity for calculation of a pooled estimate. Meta-
regression analysis was used to investigate the association
between rates and study characteristics such as year, lati-
tude and quality of study. Publication bias was assessed
using funnel plots.
Results
From 4030 electronic hits, 114 papers were read in full
and 55 selected for inclusion in the review (Additional file
2: Included studies; Additional file 3: Excluded studies).
The 55 studies [4,9-62] included 8033 cases from 1.7 ×
109 person years studied; 47 studies examined ALL MG, 9
studies examined AChR MG and 2 studies examined
MuSK MG. One study provided rates on All MG, AChR
MG and MuSK MG [54] and two provided rates for All
MG and AChR MG within the same populations [50,55].
Additional file 2 lists all included studies, descriptive sta-
tistics and quality grading.
The time period studied ranged from 1950 to 2007.
There was wide geographical distribution of studies, with
representation of all continents except Australia (Figure
1). 34/52 studies have been performed in Europe with
particular contribution from Scandinavian countries (9
studies), northern Italy (5 studies) and the UK (6 studies).
Incidence rates
For the All MG group 35 studies examined incidence. IR
ranged from 1.7 to 21.3 cases per million person-years
(Figure 2a). The forest plot illustrates a marked variation
in IR between studies, even when outliers are excluded
[51]. Pooled estimate IR (eIR) was calculated as 5.3 per
million person-years (C.I.: 4.41 - 6.12). However the
marked heterogeneity across studies, I2 = 96% (C.I.: 95-
98%) undermined the validity of the pooled estimate as a
generalisable statistic.
Likewise, heterogeneity is seen in the AChR MG group
(8 studies examined incidence, F igure 2b) with an I 2 =
100%. AChR MG IR ranged from 4.3 to 18.0 per million
person-years with a pooled AChR MG eIR of 7.3 per mil-
lion person-years (C.I.: 5.5, 7.8).
Only 2 epidemiological studies have been performed to
date on MuSK MG, in Holland [54] and Greece [62]. In
Holland IR: 0.1 per million person-years (C.I.: 0.07, 0.15),
and in Greece IR: 0.32 per million person-years (C.I.:
0.00, 1.32).
The observed heterogeneity might be explained by a
number of factors; either biological or technical. We
investigated how the effects of year of study, geographical
area of study and study quality upon observed frequency.
Linear regression of IR against the final year of study
suggests a significant correlation (Meta-regression
p:0.0001, r2:0.12) equivalent to a 3% increase per yearCarr et al. BMC Neurology 2010, 10:46
http://www.biomedcentral.com/1471-2377/10/46
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(Figure 3). In 1976 a version of the modern acetylcholine
receptor antibody assay was first described [2]. There was
no evidence of a reduction in heterogeneity when studies
were grouped into those published before (I2  = 91%,
C.I.:86, 94%) and after this date (I2 = 95%, C.I.:93, 96%).
However, the average incidence rate after 1976 (eIR = 6.5
per million person-years, C.I.:5.3, 7.9) was significantly
higher (t test: p = 0.0001) than before 1976 (eIR = 3.5 per
million person-years, C.I.: 2.7, 4.4) corresponding to an
approximate doubling (Rate ratio: 1.86, C.I.:1.22, 2.88).
There was no significant reduction in the heterogeneity
of IR when studies were grouped by geographical area:
Northern Europe I2  = 94% (C.I.:91, 95%), Southern
Europe I2 = 97% (C.I.:96, 98%), North America and Can-
ada I2 = 67% (C.I.:2, 89%). The limited numbers of studies
in Asia, Africa or Central/South American sub-groups
prevented similar analysis. There was no evidence of a
difference (p = 0.47) between the area-specific pooled
estimate IR: Northern Europe (eIR = 4.6 per million per-
son-years, C.I.: 3.8, 5.7), Southern Europe (eIR = 4.9 per
million person-years, C.I.: 4.9, 16.3), North America and
Canada (eIR = 5.3 per million person-years, C.I.: 2.8,
10.0), Central and South America (eIR = 4.32 per million
person-years, C.I.:3.8, 4.8) and Asia (eIR = 4.7 per million
person-years, C.I.: 4.2, 5.3).
There was a trend to decreasing heterogeneity with
increasing study quality: High (I2 = 76%, C.I.:49,89%),
Moderate (I2 = 89%, C.I.:85,92%) and Low (I2  = 96%,
C.I.:93, 97%). There was also evidence of a significant dif-
ference (p = 0.009) in the pooled estimate IR in the High
quality studies (eIR = 9.4 per million person-years,
C.I.:7.7, 11.4) and the pooled estimate IR in Intermediate
and Low quality studies (eIR = 4.5 per million person-
years, C.I.:3.8, 5.2).
Age and sex specific incidence rates
14 studies provided data required to allow analysis of
incidence rate by age and sex (Figure 4). A bimodal distri-
bution in IR in females was observed in 5 of 14 studies. IR
in both sexes increased with age, peaking between 60 to
80 years in all but 2 studies, with apparent male predomi-
nance in the older age group. The Asian study stands out
in that the proportion of childhood onset MG (onset < 15
years) appears to be higher in this population [26].
Prevalence rates
For the All MG group 44 studies examined prevalence.
The observed PR ranged from 15 to 179 per million (Fig-
ure 5). The estimated pooled PR is 77.7 cases per million
(C.I.: 63.98, 94.30) but, as for IR there was marked hetero-
geneity with I2 = 98% (C.I.: 97-98%) observed across stud-
ies limiting interpretation.
For the AChR MG group, 3 studies provided prevalence
data. The prevalence of AChR MG ranged from 70.6 to
163.5 per million. The marked variation between rates is
graphically depicted by the forest plot. The observed
prevalence for MuSK MG in Southern Holland is1.9 per
million (C.I.: 1.2, 2.6), representing 2% of prevalent MG
cases in the region. MuSK-MG PR in Greece is higher at
2.9 per million (95% C.I.: 1.92, 3.92).
There was a linear trend to increasing PR with year of
study (Meta-regression p = 0.0001, r2: 0.41). There is a
Figure 1 Geographical distribution of epidemiological studies in myasthenia gravis. Studies of all patients with autoimmune myasthenia gravis: 
RED. AChR MG specific studies: YELLOW. MuSK MG specific studies: PINK. Broad geographical distribution of included studies is shown with a prepon-
derance of European studies.Carr et al. BMC Neurology 2010, 10:46
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doubling in PR after 1976; RR = 2.2 (C.I.: 1.36, 3.14). PR is
on average 15-fold higher than IR for all studies (mean
PR:IR ratio: 14.7, S.D.:6.0, range: 3.5 to 34.6), there is a
trend to increasing PR:IR ratio with time (Linear regres-
sion p:0.0496, r2:0.12).
Mortality rates
Mortality rates as deaths due to MG per million person
years were examined (Additional file 2). Seven All MG
studies and 1 AChR MG study provided this information.
The MR ranges from 0.06 to 0.89 per million person-
Figure 2 Incidence rates of myasthenia gravis. Incidence rate (IR) is shown in cases per million person years with 95% confidence intervals accord-
ing to the Poisson distribution and weighting according to the random effects model. The variation between rates, or heterogeneity, leaves the esti-
mated pooled IR difficult to interpret so it is better to summarise this data using ranges. All MG: estimated pooled IR (eIR) = 5.3 cases per million person 
years (C.I.: 4.41 - 6.1), range = 1.7 to 21.3; AChR MG: eIR = 7.3 (C.I.: 5.5, 7.8), range = 4.3 to 18.0; MuSK MG: range = 0.1-0.32.Carr et al. BMC Neurology 2010, 10:46
http://www.biomedcentral.com/1471-2377/10/46
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years. The MR for AChR MG in Greece lies within this
range: 0.43 per million person-years (C.I.:0.34, 0.55).
No trend was observed for MR with year of study.
Publication bias
Symmetrical funnel plots suggest absence of marked pub-
lication bias (Additional data file 1).
Discussion
Meta-analysis of observational studies is complicated by
intrinsic differences between the populations being stud-
ied and variation in methodological quality of studies
included; nevertheless the heterogeneity across studies in
this review was marked. The degree of dissimilarity in IR,
PR and MR of MG across populations renders the calcu-
lated pooled estimates of limited generalizability and
validity. Nonetheless crude estimates are possible using
the combination of pooled estimates and the range of
observed frequencies. All MG eIR: 5.3 per million per-
son-years (C.I.: 4.41, 6.12), range: 1.7 - 21.3; ePR: 77.67
cases per million (C.I.: 63.98, 94.30), range: 15 - 179; MR
range: 0.06 - 0.89 per million person-years. AChR MG
eIR: 7.3 per million person-years (C.I.: 5.5, 7.8), range: 4.3
- 18.0; PR range: 70.6 - 163.5 per million. MuSK MG IR
range: 0.1 - 0.32 per million person-years; PR range: 1.9 -
2.9 cases per million.
In keeping with Phillips' observations [5] an increasing
trend in IR and PR with time was observed. However this
appears to be bimodal rather than linear in pattern, with
estimated rates for incidence and prevalence approxi-
mately doubling around the mid-1980 s. This may be best
explained by the influence of anti-AChR antibody recep-
tor assay upon ascertainment but improving epidemio-
logical methodology must also play a role. Our data
shows a doubling of the pooled eIR in the 'High' quality
studies when compared with that from the 'Low' and
'Intermediate' quality studies. As all 'High' quality studies
were performed since 1987 it may be more accurate to
use this data to estimate All MG incidence rate: eIR = 9.4
cases per million person years (C.I.:7.7, 11.4), range 7.4-
14.7 cases per million person years. Despite a reduction
in IR heterogeneity in this group it remained significant
suggesting that these technical issues only contribute to
the variation seen and do not explain it completely.
Several observations suggest that biological factors are
important. Age and sex specific incidences show promi-
nent differences between populations, with a peak in the
incidence of MG in young women being observed in five
of fourteen studies only. Childhood MG (onset < 15
years) was higher in the one Asian study [26] examined
by age and sex. MuSK MG was described in only two
population-based studies. Evidence from case series sug-
gests differing frequency of MuSK MG across popula-
tions, with decreasing frequency with distance from the
equator [63]. This suggests that at least some of the
observed heterogeneity might be due to differing fre-
quencies of MG subgroups between populations. Differ-
ences in population genetics may go some way to explain
the variability in rates. For example, different HLA asso-
ciations have been described in MG subsets: early onset
MG, late onset MG, MuSK-MG. These HLA associations
are different in North American/European populations
versus Asian populations [1].
The greatest heterogeneity was observed in the AChR
MG group. It might have been expected that these studies
represent a more homogenous patient group than the
broader All MG category. Five of nine studies in the
AChR group were carried out with identical methodol-
ogy. These 5 studies [55-58,60] were performed using
records of anti-AChR testing from national or regional
immunology laboratories, the assumption being that the
first positive titre for an individual correlates with disease
onset. If this were true for all AChR MG patients then any
differences observed between the IR in the studies should
be due to differences in population genetics and environ-
mental factors influencing frequency of disease. For
example the Greek study [57] and the UK study [58] were
performed with identical methodology over similar time
periods so the 3 fold difference in frequency is notable:
Greek IR 4.8 per million person years (C.I.: 4.5, 5.2), UK
IR 18.0 per million person years (C.I.: 17.4, 18.6). How-
ever this does not take into account the differing levels of
access to a neurologist and access to serological tests
between populations.
PRs were on average 15 fold higher than IR across stud-
ies. This difference could be explained by good survival
and low mortality associated with MG, however, an older
age of symptom onset probably limits overall survival
therefore influencing PR. We also saw a trend to increas-
Figure 3 Incidence rate and prevalence rates with time. IR in cases 
per million person years and PR in cases per million persons are plotted 
against final year of study. The area each circle is proportional to the 
size of the study population.Carr et al. BMC Neurology 2010, 10:46
http://www.biomedcentral.com/1471-2377/10/46
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ing prevalence compared to incidence (PR: IR ratio) with
year of study which may suggest improving care and sur-
vival and increasing life expectancy.
It is notable that no data were available on seronegative
MG. Its epidemiology, therefore, remains undescribed.
Conclusions
IR  a n d  P R  o f  M G  va ry  m a r k ed l y  be t w ee n  po p u l a t i o n s
studied. Pooled incidence rates cannot readily be extrap-
olated to unstudied populations. The heterogeneity may
be explained in part by methodological differences but
the data also suggest that there are biological factors to
Figure 4 Age and sex specific incidence rates. Age and sex specific IR is shown in cases per million person years. An increasing frequency of disease 
with age is seen in all populations. However, only 5 out of 14 shown a bimodal distribution in IR with the peak in younger women not observed in the 
remaining 9 studies.Carr et al. BMC Neurology 2010, 10:46
http://www.biomedcentral.com/1471-2377/10/46
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account for differences. Detailed population-based data
on serological and pathological sub-types of MG within
complete populations are largely lacking.
Future studies should concentrate on accurate clinical
case definition over adequate time periods in sufficiently
sized populations. Factors influencing ascertainment
such as equity of access to appropriate specialists in neu-
rology and ophthalmology should be noted. National lab-
oratory records of positive AChR or MuSK antibody
titres used in isolation probably under-estimate rates so
Figure 5 Prevalence rates of myasthenia gravis. Prevalence rate (PR) is shown in cases per million persons with 95% confidence intervals (95% C.I.) 
according to the Poisson distribution and weighting according to the random effects model. All MG ePR = 77.67 cases per million (C.I.: 63.98, 94.30), 
range = 15 to 179 cases per million; AChR MG: range = 70.6 to 163.5; MuSK range = 1.9-2.9.Carr et al. BMC Neurology 2010, 10:46
http://www.biomedcentral.com/1471-2377/10/46
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multiple sources of ascertainment should be used in
order to optimise case identification. Serological sub-
group classification is important and recently developed
assays for the identification of MuSK MG and MG with
antibodies to AChR clustered with rapsyn [64] will aid
diagnosis and sub-group phenotype description.
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